glp 1 and allodynia Frontiers Allodynia is an increased skin

A case series of 17 patients reported reduced symptoms in more than 90% of patients following intra-articular knee BPC-157 injections for tendon and ligament injuries at minimum of 6-month follow-up

van Bruggen R

It could be that the 3-fold higher abundance of Akkermansia muciniphila in MCS patients decreases their gut mucosal barrier and activates the bodys immune response.[ref] Now lets take a look at how your genetic variants increase or decrease your susceptibility to MCS

By targeting the bodys hunger signals, GLP-1 therapies can reduce caloric intake, support blood sugar control, and promote a feeling of fullness